rituximab

Antirheumatic drugs, B cell depletion and critical COVID-19: correspondence on ‘Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine’ by Mathian et al
Quirin Notz, Patrick Meybohm, Peter Kranke, Dirk Weismann, Christopher Lotz, Marc Schmalzing

Annals of the Rheumatic Diseases Aug 2020, annrheumdis-2020-218778; DOI: 10.1136/annrheumdis-2020-218778
Efficacity of a sequential treatment by anti-CD 20 monoclonal antibody and belimumab in type II cryoglobulinaemia associated with primary Sjögren syndrome refractory to rituximab alone
Kevin Chevalier, Rakiba Belkhir, Raphaele Seror, Xavier Mariette, Gaetane Nocturne

Annals of the Rheumatic Diseases Sep 2020, 79 (9) 1257-1259; DOI: 10.1136/annrheumdis-2020-217481
Mild COVID-19 in ANCA-associated vasculitis treated with rituximab
Silvia Suárez-Díaz, Claudia Morán-Castaño, Rubén Coto-Hernández, Lourdes Mozo-Avellaneda, Carlos Suárez-Cuervo, Luis Caminal-Montero

Annals of the Rheumatic Diseases Aug 2020, annrheumdis-2020-218246; DOI: 10.1136/annrheumdis-2020-218246
Treatment of patients with inflammatory rheumatic diseases with rituximab should be carefully considered during the SARS-CoV-2/COVID-19 pandemic. Response to: ‘Persistence of rT-PCR-SARS-CoV-2 infection and delayed serological response, as a possible effect of rituximab according to the hypothesis of Schulze-Koops et al’ by Benucci et al
Hendrik Schulze-Koops, Klaus Krueger, Inka Vallbracht Vallbracht, Rebecca Hasseli, Alla Skapenko

Annals of the Rheumatic Diseases Aug 2020, annrheumdis-2020-218686; DOI: 10.1136/annrheumdis-2020-218686
Persistence of rT-PCR-SARS-CoV-2 infection and delayed serological response, as a possible effect of rituximab according to the hypothesis of Schulze-Koops et al
Maurizio Benucci, Luca Quartuccio, Francesca Li Gobbi, Arianna Damiani, Valentina Grossi, Maria Infantino, Mariangela Manfredi

Annals of the Rheumatic Diseases Aug 2020, annrheumdis-2020-218590; DOI: 10.1136/annrheumdis-2020-218590
Clinical course and outcome of COVID-19 in patients with rheumatic diseases: are all biological disease-modifying antirheumatic drugs alike? Response to: ‘Increased risk for severe COVID-19 in patients with inflammatory rheumatic diseases treated with rituximab’ by Schulze-Koops et al
Sara Monti, Carlomaurizio Montecucco

Annals of the Rheumatic Diseases Jun 2020, annrheumdis-2020-218148; DOI: 10.1136/annrheumdis-2020-218148
Increased risk for severe COVID-19 in patients with inflammatory rheumatic diseases treated with rituximab
Hendrik Schulze-Koops, Klaus Krueger, Inka Vallbracht, Rebecca Hasseli, Alla Skapenko

Annals of the Rheumatic Diseases Jun 2020, annrheumdis-2020-218075; DOI: 10.1136/annrheumdis-2020-218075
Severe COVID-19-associated pneumonia in 3 patients with systemic sclerosis treated with rituximab
Jérôme Avouac, Paolo Airó, Nicolas Carlier, Marco Matucci-Cerinic, Yannick Allanore

Annals of the Rheumatic Diseases Jun 2020, annrheumdis-2020-217864; DOI: 10.1136/annrheumdis-2020-217864
Response to: ‘Severe COVID-19 associated pneumonia in 3 patients with systemic sclerosis treated with rituximab’ by Avouac et al
Philippe Guilpain, Clément Le Bihan, Vincent Foulongne, Patrice Taourel, Nathalie Pansu, Alexandre Thibault Jacques Maria, Boris Jung, Romaric Larcher, Kada Klouche, Vincent Le Moing

Annals of the Rheumatic Diseases Jun 2020, annrheumdis-2020-217955; DOI: 10.1136/annrheumdis-2020-217955
Rituximab for granulomatosis with polyangiitis in the pandemic of covid-19: lessons from a case with severe pneumonia
Philippe Guilpain, Clément Le Bihan, Vincent Foulongne, Patrice Taourel, Nathalie Pansu, Alexandre Thibault Jacques MARIA, Boris Jung, Romaric Larcher, Kada Klouche, Vincent Le Moing

Annals of the Rheumatic Diseases Apr 2020, annrheumdis-2020-217549; DOI: 10.1136/annrheumdis-2020-217549

Main menu

rituximab

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

rituximab

Pages